Pharmaxis had a horror day yesterday with its share price nearly halving in value after it revealed that the panel which advises the US FDA gave its drug to treat cystic fibrosis Bronchitol a negative recommendation.

Deutsche Bank analyst David Low cut his call to “sell" given the opinion raises the risk substantially for a rejection by the FDA.